Avacta Therapeutics said on Monday that it has opened the phase one clinical trial of its second oncology pipeline candidate, ...

David Reese believes that AI’s greatest impact will come from improving the thousands of human-led decisions. If Reese, the ...

Definium Therapeutics (NASDAQ:DFTX) outlined its clinical pipeline and upcoming data catalysts at the Leerink Partners Global ...

Diagnosed with severe spina bifida, baby Nixon receives pioneering stem cell fetal surgery, gaining mobility beyond expectations and hope for the future.

Bicycle Therapeutics is letting more air out of its operations, with plans to deflate its employee count by about 30% and ...

An expert involved in the first successful gene therapy trial for Huntington's Disease discusses the trial results and ...

Stoke Therapeutics is developing a drug designed to reduce seizures and restore some of their lost developmental function.

GLP-1 drugs like Ozempic are reshaping performance, expectations and fairness at work. As access expands, leaders must ...

He wrote a book on anti-white bias. The White House noticed.

Boundless Bio's first direct ecDNA-targeting asset, is entering clinical trials with promising preclinical efficacy. Check out why BOLD stock is a buy.

Cognition Therapeutics, Inc., (the “Company” or “Cognition”) (NASDAQ: CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, presented an analysis from the Phase 2 ...

Quarterly Adjusted EBITDA -- $4.9 million, a $6.3 million improvement from negative $1.4 million in the prior year, with a ...